DRKS00003518已完成2 期
Prospective randomized multicenter phase II study of pulmonalfiliae metastases (poor-prognosis) in clear cell renal cell carcinoma + / - adjuvant Sunitinibtherapie than 1 year - SMAT - AN 20/04 - SMAT
niversitätsklinikum Essen0 个研究点目标入组 10 人开始时间: 2012年1月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •functionally acceptable surgical risk
- •- Women in conceptional age: negative pregnancy test and adequate contraception
- •- Adequate hematologic, renal, hepatic and coagulation-physiological functions
- •- Amylase/ Lipase < 1,5 x upper limit of normal
- •- Informing the patient about the study and the present written consent to participate after clarification in accordance with the stipulations of AMG(german drug law), and the principles of GCP (informed consent)
- •- Patient compliance and geographic proximity to allow adequate follow-up
排除标准
- •- Presence of other metastases outside the lung
- •- progress in the 12-week sunitinib therapy before resection of metastases
- •- R1 or R2-finding in resection of metastases
- •- Dialysis after nephrectomy
- •- Previous or existing serious cardiovascular (grade III - IV according to NYHA(New York Heart Association)) disease, active angina pectoris or ischemia, myocardial infarction within previous 6 months , uncontrolled hypertension(RR diastolic >= 120 mmHg(Millimeters of mercury))
- •- serious hematopoetic (e.g. serious Bone marrow aplasia), pulmonary, hepatic or renal Disease
- •- Stroke within the previous six months
- •- Patients with poorly controlled diabetes mellitus
- •- Serious bacterial or fungal infections
- •- chronic hepatitis B or C, HIV(human immunodeficiency virus) infection
- •- autoimmune disease
- •- prior organ transplantation
- •- prior autologous bone marrow transplant or stem cell transferred within the last 4 months before study
- •- Neuropsychiatric diseases that affect patient compliance
- •- Manifesto, second malignancy or other malignancy within the past 5 years (except basal cell carcinoma, carcinoma in situ of the cervix, incidental prostate carcinoma, superficial urothelial Ca pTaG1-2 and pT1G1)
- •- Therapy with immunotherapeutic agents including monoclonal antibodies, cytotoxic drugs or hormones (other than bisphosphonates and oral contraceptives) within the last 4 weeks prior to enrollment. Previous use of inhibitors of Ras/Raf-, MEK kinase, AKT kinase and mTOR inhibitors or induction of Farnesyltransferase
- •- Previous use of angiogenesis inhibitors such as VEGF / VEGFR, PDGF / PDGFR and other key molecules of angiogenesis
- •- parallel treatment with rifampicin
- •- Participation in other treatment studies in the last 4 weeks
研究者
相似试验
进行中（未招募）
不适用
Phase II prospective randomized multicenter study of Folfiri versus Folfiri Cox-2 inhibitor versus Folfiri followed by Cox-2 inhibitor in the first-line treatment of colo-rectal cancerEUCTR2004-000591-13-ITISTITUTO ONCOLOGICO ROMAGNOLO159
已完成
2 期
Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapyC92.9Myeloid leukaemia, unspecifiedDRKS00000733niversitätsklinikum Freiburg204
进行中（未招募）
1 期
Clinical trial of low-dose decitabine (DAC) administered alone or in combination with the valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for standard chemotherapyEUCTR2009-009916-33-DEniversity Medical Center Freiburg200
进行中（未招募）
1 期
Prospective Randomized Multicenter Phase II Trial toInvestigate Intensified Neoadjuvant Chemotherapy inLocally Advanced Pancreatic Cancerocally advanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2013-004796-12-DEAIO-Studien-gGmbH168
进行中（未招募）
1 期
A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.Refractory wtKRAS metastatic colorectal cancerMedDRA version: 14.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000167-25-FRICANCER75